Press release -
STADA Health Report 2023: Invitation to the international hybrid STADA press conference
Dear Editorial Team
The fifth international STADA Health Report focuses on how Europeans are caring for their own health in times of crisis – by taking preventive and not merely reactive measures.
The first results of the representative online study conducted by the market research institute Human8 Consulting on behalf of STADA Arzneimittel AG will be presented to you at our international hybrid press conference on 19 September 2023.
- Over 30 questions on current health topics covering prevention, medicine supply shortages, current and future pharmacy services, health knowledge, and many more
- Around 32,000 respondents from 16 European countries
- Hybrid press conference (English) at 11 am (CEST) on 19 September
In 2022, the STADA Health Report illustrated that Europeans‘ mental well-being had suffered, especially due to the pandemic. This year‘s study examines the role that preventive health plays in the lives of Europeans – especially in times of crisis – and how much they know about offers and recommendations for preventive measures as well as their proficiency in basic health matters, among many other topics.
We look forward to seeing you there.
Kind regards,
Your STADA Press Team
Topics
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2022, STADA achieved group sales of EUR 3,797.2 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of 31 December 2022, STADA employed 13,183 people worldwide.
